Emergent BioSolutions Inc. (NYSE: EBS) today announced the exercise of contract option and modification valued at approximately $20 million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback